ArticleBlood neoplasia2026
CD20 negativity at the start of second-line therapy predicts a shorter overall survival in B-cell lymphomas.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD20 expression is a hallmark of B-cell lymphomas and the target of anti-CD20 monoclonal antibodies. Although CD20 negativity at second-line therapy initiation has been reported, its prevalence and prognostic impact in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) remain uncertain. We assessed the prevalence of CD20 negativity at second-line initiation and its association with overall survival (OS) in a nationwide cohort. We included consecutive Danish adults with DLBCL, FL, or MCL who received rituximab-based first-line therapy and were diagnosed between 2005 and 2023, for whom CD20 expression was evaluated at second-line initiation. The primary endpoint was OS from second-line therapy, stratified by CD20 status. Multivariable Cox regression analysis was adjusted for age, sex, and subtype-specific international prognostic indices. Among 1375 patients (814 with DLBCL, 339 with FL, 222 with MCL), 168 (12.2%) were CD20
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.